Identification
Instrument name
KIADIS
Symbol
KDS
ISIN code
NL0011323407
Exchange / Market
Euronext
Trading location
Amsterdam
Brussels
Products family
Stocks
Capitalization compartment
Compartment C
ICB
Biotechnology
Website address
http://www.kiadis.com
Operation
IPO date
Issue type
Initial Public offering
Cat├ęgorie
IPO
Price range
EUR 11.00 - EUR 13.75

Company profile

Kiadis Pharma is developing potentially life saving therapies for patients with late-stage blood cancers, who are in need of a transplant, an area of significant need. Kiadis Pharma is building a fully integrated biopharmaceutical company to maximize the potential of ATIR, the company's proprietary cell-based immunotherapy platform. The lead program, ATIR101, is a patient-specific T-cell product delivered following a haploidentical hematopoietic stem cell transplant in order to support the patient's newly transplanted immune system. ATIR101 is under review for potential marketing authorization in the EU based on phase 2 clinical trial data. Kiadis Pharma is currently evaluating ATIR101 in a global phase 3 trial to support filing for approval in the United States.

Source: Cofisem - Last Update: 13 Sep 2019
Key Executives
Chief Executive Officer Arthur Lahr
Company Secretary James Joy
Chief Financial Officer Scott Holmes
Investor Relations Amy Sullivan
Human Resources Director Mark Schaefer
Source: Cofisem - Last Update: 13 Sep 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales
Income from ordinary activities
Operating income -25,201 -16,120 -11,408 -16,007 -6,168
Cost (net) of financial indebtedness -4,302 -2,285 -1,558 -1,344 -1,045
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -29,801 -17,038 -14,794 -16,457 -7,813
Net income (Group share) -29,801 -17,038 -14,794 -16,457 -7,813
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 13 Sep 2019
Shareholder information
FIL 2.96 %
Source: Cofisem - Last Update: 30 May 2019